Inhibikase Therapeutics (IKT) vs Sutro Biopharma (STRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sutro Biopharma (STRO) has outperformed Inhibikase Therapeutics (IKT) over the past year, gaining 2.4% versus a loss of 11.4%. Over five years, IKT leads with a -89.3% price change compared with -94.7% for STRO. Inhibikase Therapeutics is the larger company by market cap ($185.2 million vs $142.8 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IKT | STRO |
|---|---|---|
| Share price | $1.32 | $8.60 |
| Market cap | $185.16M | $142.77M |
| 1-day change | +1.54% | -1.38% |
| YTD return | -35.61% | -25.67% |
| 1-year return | -11.41% | +2.38% |
| 5-year return | -89.32% | -94.68% |
| EPS (TTM) | $-0.40 | $-12.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $102.48M |
| Revenue growth (YoY) | — | +65.18% |
| Net income (latest FY) | $-48.26M | $-191.09M |
| Operating margin | — | -154.53% |
| Net margin | — | -186.45% |
| 52-week high | $2.61 | $43.85 |
| 52-week low | $1.28 | $7.15 |
| Distance from 52-week high | -49.43% | -80.39% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +320.45% | +419.65% |
| Average volume | 584.27K | 304.90K |
| Shares outstanding | 140.27M | 16.60M |
| Employees | 35 | 129 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- STRO has outperformed IKT by 13.8 percentage points over the past year.
About Inhibikase Therapeutics
IKT stock →Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 35 employees
About Sutro Biopharma
STRO stock →Sutro Biopharma, Inc. operates as an oncology company.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 129 employees
IKT vs STRO FAQ
Which is bigger, Inhibikase Therapeutics or Sutro Biopharma?
Inhibikase Therapeutics (IKT) is larger, with a market capitalization of $185.16M compared with $142.77M for Sutro Biopharma (STRO).
Which stock has performed better over the past year, IKT or STRO?
STRO returned +2.38% over the past 12 months, compared with -11.41% for IKT (price return, excluding dividends). Past performance does not predict future results.
Are Inhibikase Therapeutics and Sutro Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.